Some of the earliest theories of cancer predisposition have proposed a close relationship between the processes that control normal and malignant development. More recent work has established that the cellular pathways critical to embryonic development do indeed contain a number of genes which function as tumour-suppressor genes. Twenty-seven years ago. Knudson (1971) first proposed the existence of tumour-suppressor genes (TSGs) based on an analysis of the predisposition to retinoblastoma Since that time. nearly 20 TSGs. including the human retinoblastoma gene (RB) itself, have been identified and cloned and. in many cases. mouse models of gene deficiency have been generated by gene targeting. For example. animals heterozygous for Rb-i (the mouse homologue of the human RB gene) develop tumours with almost 100% penetrance. This strain has also demonstrated the absolute requirement for Rb-i in development. as homozygous null animals die at day 13 of gestation. (e.g. Clarke et al, 1992) . Other TSGs have also revealed essential developmental roles. Thus. Apc-deficient embryos die shortly after implantation (Moser et al. 1989 ) and p53-deficient mice show increased rates of neural tube abnormality (Armstrong et al. 1995 : Sah et al. 1995 .
The Smad4 gene (also termed DPC4) is located on chromosome 1 8q21 and is perhaps the most recent addition to this group of genes that show both developmental and tumour-suppressor functions. In 1996. Smad4 was discovered after genetic analysis of a panel of pancreatc carcinomas, earning its original name of DPC4 from the fact that it was homozygously deleted in a third of the cancers.
hence deleted in pancreatic carcinoma-4 (Hahn et al, 1996a) .
Investigation of the gene showed that it had sequence homology to the Drosophila melanogaster mothers against dpp (MAD) protein. a transforming growth factor P (TGF-f) signalling homologue (Hahn et al. 1996a) . and the Caenorhabditis elegans Mad homologues sma-2. sma-3 and sma4 (Sekelsky et al. 1995) . The presence of Received2 March 1998 Revised 14 May 1998 Accepted 19 May 1998 Corespondence to: AR Clarke strong homology to these genes implies that. as well as being a tumour-suppressor gene. Smad4 is important in TGF-0 signalling and mammalian development. Its association with human neoplasia may entirely be a consequence of this significance. as is becoming apparent for several other TSGs.
TGF-P family
The TGF-0 superfamily is one of the largest groups of polypeptide growth and differentiation factors and mediates a wide range of biological processes in both vertebrates and invertebrates (Kingsley. 1994) . Various functional criteria have been used to group the superfamily (of currently around 25 different molecules) into three classes: TGF-ps. activins and bone morphogenetic proteins (BMPs). Different members of these groups are variously implicated in the regulation of wound healing. immune responses and. more importantly. in control of growth pathways. The TGF-j family itself consists of at least five genes encoding distinct proteins in vertebrates. referred to as TGF-j1-5. The biological effects of TGF-P are mediated by specific TGF-4 receptors at the surface of the target cells. which fall into two classes dependent upon structure. The two types of receptor. both functional serine/threonine kinases. form heteromeric complexes which bind different ligands and initiate different intracellular responses. Essentially. the type I receptors appear to be less selective and can bind different ligands dependent on the more limited ligand specificity of the type II receptor with which they associate (Wrana et al. 1992a.b; Attisano et al. 1993 : Massague et al. 1993 . Association of the two receptors leads to downstream phosphorylation events which eventually lead to transcription of the appropriate TGF-, superfamily gene (Maciassilva et al. 1996) (Lagna et al. 1996 : Heldin et al. 1997 : Figure 1 ).
MADs
The primary structures of MAD proteins do not contain any motif that clearly indicates their function. MADs are proteins of approximately 450 amino acids with highly conserved N-and C-terminal domains and a variable proline-rich intervening region. Smad4 has a structure consistent with a MAD-related protein: there are conserved N-and C-terminal regions (termed MHI and MH2 respectively) connected by a poorly conserved linker domain rich in serine. threonine and proline residues . This structure seems to suggest that the MH domains share a tertiary structure critical to the regulation and function of the protein.
In support of this. all the mutations identified in genetic screens map either to the MH 1 or the MH2 domain. and often involve alterations in highly conserved residues. Although MAD function within the nucleus is still largely unclear. it has been observed that the C-domains of various MAD proteins (and Smad4) display taanscriptional activity when bound to DNA via a GAL4 DNA binding domain (Liu et al. 1996) . The importance of the C-terminal region is ftuther emphasized by studies of malignancy (see below). which reveal that the primary hotspot for Smad4 mutations is within the C-terminal domain (Savage et al. 1996) . This is confirmed by the recently described crystal structure of the Smad4 Cterminal domain. which shows that the majority of tumour-derived mutations map to five amino acids that are involved in essential intermolecular contacts (Shi et al. 1997 ). These observations raise the possibility that MAD proteins function by transactivation. In Xenopus embryos. Smad2 has been shown to interact with FAST-1. a transcription factor with a novel winged helix stucture. Furthermore.
Smad4 co-immunoprecipitates with this complex (Chen et al. 1997) .
Although these data suggest a role for Smads in regulating transcnption. the exact nuclear function of these heteromeric Smad complexes remains largely unknown. It has been shown that Smad3 and Smad4 can form a DNA-binding complex that activates transcription of a reporter gene. Furthermore. it has been demonstrated that MAD protein can bind DNA (Xin et al. 1996) . and Smad4 itself has been shown to be a DNA-binding protein (Liu et al. 1997) . Recently. it has emerged from functional assay studies in a Smad4 null cell line that the molecule does indeed appear to have distinct activation and ligand response domains within it (Caestecker et al. 1997) . This suggests a model for Smad4 similar to other archetypal signalling molecules: in the absence of ligand. the N-terminal domain and possibly the middle linker region may obscure the activation domain at the C-terminal end of the molecule. After ligand activation. this results in exposure of the activation domain and may allow the binding of other molecules. The apparent role of Smad4 appears to be in mediating the actions of the other Smads.
Perhaps one of the most powerful indicators of the importance of Smad4's role comes from some recently published papers by Sirard et al (1998) and Takaku et al (1998 Schutte et al (1996) Verbeek et at (1996) Sch utte et at (1996) RozenbJum et at (1997) Hahn et at (1996) Verbeek et at (1996) Watanabe et at (1997) British Journal of Cancer (1998) (Ikezoe et al. 1998 ) and also in lunga carcinomas (approximately 4% (Uchida et al. 1996) . Disruption of the Smad2 gVene during development results in a complete loss of embryonic gaerm-layer tissues (Waldrip et al. 1998) . confiainr that Smad2. like Smade.
has an essential role to play in development.
TGF-w is well known for its antiproliferative activits in the majorityof mammalian epithelial cells. and loss of TGF-l responsiveness is documented to be associated with agaressive neoplasms (Pommier. 1992 : Arteaga et al. 1993 : Polyak. 1996 suggtests that Smad4-dependent malignancy may arise after disruption of these key reaulatory mechanisms. In summary. Smado has been shown to be a critical effector of the TGF-response. a role apparently mediated through its control or ither Smad genes. Smad4 appears to be the key retulatory protein of this signalling pathwsay. ultimately controlling transcription driven by the TGF-e superfamily. Loss of Smad4 has been shown to be associated primanly with pancreatic maignancy and to a lesser extent with clcoloret ancer. Its involvement in other cancer types is currently either 'ery limited or unproven. Characterization of the role played by Smad4 will throw light on the basic biology of pancreatic neoplasia and should also suggest new therapeutic approaches to this disease. Finally, a determination of the role played by Smad4 in malignancy should provide an excellent paradigm for other components of this signalling pathway. perhaps leading to the identification of a family of genes with related TSG activity.
